抗人胸腺细胞免疫球蛋白(Anti-thymocyte Globulin (Rabbit)) - 在研适应症：器官移植排斥，细菌感染，移植物抗宿主病_专利_临床

概要

基本信息

药物类型

免疫球蛋白

别名

Anti-human thymocyteimmunoglobulin, Rabbit、Thymoglobulin、Thymoglobuline

+ [2]

靶点-

作用方式

抑制剂

作用机制

胸腺细胞抑制剂

治疗领域

免疫系统疾病感染血液及淋巴系统疾病+ [2]

在研适应症

器官移植排斥细菌感染移植物抗宿主病+ [6]

非在研适应症

急性移植物抗宿主病急性髓性白血病肾移植急性排斥反应+ [22]

原研机构

Genzyme Corp.

在研机构

Sanofi KKSanofi-Aventis Australia Pty Ltd.

Genzyme Corp.

+ [1]

非在研机构

Sanofi

权益机构-

最高研发阶段批准上市

首次获批日期

韩国 (1993-01-19),

再生障碍性贫血心脏移植排斥反应肾移植排斥反应

最高研发阶段(中国)-

特殊审评孤儿药 (美国)、孤儿药 (韩国)

登录后查看时间轴

关联

229

项与抗人胸腺细胞免疫球蛋白相关的临床试验

NCT06872333

/ Recruiting临床2期IIT

Allogeneic Hematopoietic Stem Cell Transplant for Patients With High Risk Hemoglobinopathies and Other Red Cell Transfusion Dependent Disorders

A single center, open label, interventional, phase II trial for donor transplant for high risk hemoglobinopathies and other red cell transfusion dependent disorders utilizing allogeneic hematopoietic stem cell transplantation (HSCT) regimens.

开始日期2024-11-19

申办/合作机构

University of Minnesota Masonic Cancer Center

NCT06083129

/ Not yet recruiting临床3期IIT

Phase III Study Comparing GVHD Prophylaxis With ATG-thymoglobulin to ATLG-grafalon in Elderly Patients With Acute Myeloid Leukemia or Myelodysplasic Syndrome and Receiving an Allogeneic Hematopoietic Stem Cell Transplantation With a 10/10 HLA Matched Unrelated Donor Following a Reduced Intensity Conditioning Regimen by Fludarabine-treosulfan

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative therapy in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Most of the patients requiring an allo-HSCT are above 50 years of age and are transplanted with a reduced intensity conditioning (RIC) regimen. The optimal RIC and Graft Versus Host Disease (GVHD) prophylaxis regimen allowing a good control of the disease while preventing GVHD remains to be determined for elderly patients. A phase III trial comparing the conventional RIC fludarabine-busulfan 2 days to fludarabine-treosulfan demonstrated an advantage for the flu-treosulfan arm in terms of event free survival (EFS), that should therefore be considered as the new standard of RIC regimen for AML and MDS. GVHD prevention has a crucial role in post-transplant outcomes by potentially interfering with the graft-versus-leukemia (GVL) effect and immune reconstitution. Anti-thymocyte globulins (ATG) are recommended to reduce the risk of acute and chronic GVHD in transplants performed with matched unrelated donors. However, the optimal type of ATG between the 2 approved brands (ATG-thymoglobulin and ATLG-grafalon) displaying distinct characteristics and the optimal dose of ATG are still unknown. In a retrospective study of patients transplanted mainly with RIC with matched related and unrelated donors for haematological malignancies, we observed that Anti-T lymphocyte globulin (ATLG) was associated with a reduction of grade II-IV acute GVHD in comparison to ATG without increasing the incidence of relapse.
In this phase III randomised study, we propose to compare GVHD prevention with ATG versus ATLG in AML and MDS patients above 50 years of age transplanted with a matched unrelated donor following a fludarabine-treosulfan RIC, with the hypothesis that ATLG would better control GVHD in this population of patients thus limiting the risk of morbidity and mortality of the procedure.

开始日期2023-11-01

申办/合作机构

Assistance Publique des Hôpitaux de Paris SA

NCT05743400

/ Recruiting临床4期IIT

Thymoglobulin® Pharmacokinetics for Graft-versus Host Disease in Children and Adults Undergoing Hematopoietic Stem Cell Transplantation

Thymoglobulin is widely applied as serotherapy in order to prevent acute graft-versus-host disease (GvHD) and graft rejection in patients undergoing non-Human Leukocyte Antigen (HLA)-identical hematopoietic stem cell transplantations (HSCT), with a delicate balance between prevention of GvHD and the promotion of immune reconstitution. Thymoglobulin is known as a drug with high pharmacokinetic (PK) variability. This variability influences drug exposure, which in turn determines the drug response of pharmacodynamics (PD). In order to maintain efficacy while reducing adverse effects of drugs across the entire age range, identification of the PK/PD relationships and the effect of growth and maturation on the different PK and PD parameters involved are crucial.
The investigators hypothesise that a better knowledge of Thymoglobulin PK and its covariates would help to individualise dosage regimen and would improve clinical outcomes, such as GvHD and immune reconstitution.
The investigators aim to build a population PK model of Thymoglobulin in order to study PK variability and its covariates. This model will help in optimizing dosage regimen in an individually way.

开始日期2023-09-25

申办/合作机构

Hospices Civils de Lyon

100 项与抗人胸腺细胞免疫球蛋白相关的临床结果

登录后查看更多信息

100 项与抗人胸腺细胞免疫球蛋白相关的转化医学

登录后查看更多信息

100 项与抗人胸腺细胞免疫球蛋白相关的专利（医药）

登录后查看更多信息

5,172

项与抗人胸腺细胞免疫球蛋白相关的文献（医药）

2025-12-31·ANNALS OF MEDICINE

Comparative retrospective analysis of cord blood transplantation with ATG-containing conditioning regimens and haploidentical stem cell transplantation: similar survival outcomes with reduced incidence of GVHD

Article

作者: Liu, Wei ; Wang, Bingjie ; Li, Yuan ; Ren, Hanyun ; Liang, Zeyin ; Dong, Yujun ; Yin, Yue ; Wang, Qingyun ; Wang, Qingya ; Liu, Yongjia

BACKGROUND:

Cord blood (CB) is widely used in treating haematologic disorders due to its broad availability, tolerance to significant histocompatibility antigen disparities, and low incidence of chronic graft-versus-host disease (cGVHD). The cord blood transplantation (CBT) with anti-thymocyte globulin (ATG)-containing conditioning regimens shows promise in this regard.

METHODS:

We conducted a retrospective review of data from patients who underwent CBT at our centre from August 2003 to December 2022. Patients undergoing CBT with ATG were matched with those who received HLA-haploidentical haematopoietic stem cell transplantation (haplo-HSCT). Propensity score matching (PSM) was utilized to form 105 matched pairs (140 patients) for comprehensive trial analysis.

RESULTS:

The cumulative incidence of neutrophil and platelet engraftment was significantly lower in the CBT group. Patients in the CBT group exhibited significantly lower incidences of grade II-IV acute GVHD (aGVHD) and cGVHD compared to the haplo-HSCT group (8.57% vs. 29.52%, p = 0.012; 20% vs. 39.05%, p = 0.031). The overall survival (OS) rate for the CBT and haplo-HSCT groups showed no significant difference. In patients with leukaemia, the CBT cohort showed better OS, GVHD-free and relapse-free survival (GRFS), as well as a lower incidence of disease relapse, although there was no statistical difference.

CONCLUSION:

Our single-centre retrospective long-term follow-up investigations indicated that although the implantation rate of CBT is lower than that of haplo-HSCT, patients undergoing CBT with ATG-containing conditioning regimens may have a comparable overall survival with a lower risk of GVHD compared to those undergoing haplo-HSCT.

2025-12-01·Blood Research

Post-transplant cyclophosphamide plus anti-thymocyte globulin decreased serum IL-6 levels when compared with post-transplant cyclophosphamide alone after haploidentical hematopoietic stem cell transplantation

Article

作者: Jo, Deog-Yeon ; Kang, Sora ; Lee, Myung-Won ; Ryu, Hyewon ; Seo, Wonhyoung ; Lee, Hyo-Jin ; Koh, Jeong Suk ; Lee, Sang-Woo ; Lee, Seul Bi ; Heo, Bu Yeon ; Eun, Hyuk Soo ; Pham, Thi Thuy Duong ; Choi, Suyoung ; Yun, Hwan-Jung ; Song, Ik-Chan ; Kim, Chul Hee

Abstract:

Background:

Post-transplantation cyclophosphamide (PTCy) and anti-thymocyte globulin (ATG) are common prophylactic strategies for graft-versus-host disease (GVHD) after haploidentical hematopoietic stem cell transplantation (haplo-HSCT). Interleukin (IL)-6 is a surrogate marker for cytokine release syndrome (CRS) and acute GVHD.

Method:

The clinical outcomes and complications of haplo-HSCT with PTCy plus ATG versus PTCy monotherapy were compared according to serum IL-6 levels at Chungnam National University Hospital (Daejeon, South Korea) from January 2019 to February 2023.

Results:

Forty patients who underwent haplo-HSCT were analyzed. A significant difference in IL-6 levels was observed between the PTCy plus ATG and PTCy alone groups (7.47 ± 10.55 vs. 117.65 ± 127.67; p = 0.003). More patients in the PTCy plus ATG group had a CRS grade of 0 than in the PTCy alone group (p < 0.001). Serum IL-6 levels were associated with grades II–IV acute GVHD (r = 0.547, p < 0.001). The cumulative incidence (CI) of grades II–IV acute GVHD was significantly higher in the PTCy alone group (67.9% vs. 4.8%; p < 0.001). No significant difference in the CI for chronic GVHD was detected between the PTCy plus ATG and PTCy alone groups (72.1% vs. 82.0%; p = 0.730). The CI of 1-year non-relapse mortality was significantly higher in the PTCy alone group than in the PTCy plus ATG group (42.2% vs. 15.9%; p = 0.022). The 1-year overall survival (OS) was significantly better in the PTCy plus ATG group (75.9% vs. 35.3%; p = 0.011). The 1-year GVHD-free, relapse-free survival rate was 29.4% in the PTCy alone group and 54.0% in the PTCy plus ATG group (p = 0.038).

Conclusion:

Serum IL-6 levels were higher in the PTCy alone group than in the PTCy plus ATG group. The addition of ATG before stem cell infusion affected IL-6 levels and reduced the incidences of CRS and grade II–IV acute GVHD in haplo-HSCT patients. This study suggests that PTCy plus ATG as GVHD prophylaxis in haplo-HSCT is beneficial in terms of clinical outcomes and complications of HSCT.

2025-07-01·Life Science Alliance

DNA methylation predicts infection risk in kidney transplant recipients

Article

作者: Reed, Elaine F ; Hsu, Fei-Man ; Pellegrini, Matteo ; Pickering, Harry ; Schaenman, Joanna M ; Rubbi, Liudmilla ; Thompson, Michael

Kidney transplantation (KTx) is the method of choice for treating kidney failure. Identifying biomarkers predictive of transplant (Tx) outcomes is critical to optimize KTx; however, the immunosuppressive therapies required after KTx must also be considered. We applied targeted bisulfite sequencing (TBS-seq) to PBMCs isolated from 90 patients, with samples collected pre- and post-Tx (day 90), to measure DNA methylation changes. Our findings indicate that the PBMC DNA methylome is significantly affected by induction immunosuppression with anti-thymocyte globulin (ATG). We discovered that the risk of infection can be predicted using DNA methylation profiles, but not gene expression profiles. Specifically, 515 CpGlociassociated with 275 genes were significantly impacted by ATG induction, even after accounting for age, sex, and cell-type composition. Notably, ATG-associated hyper-methylation down-regulates genes critical for immune response. In conclusion, this clinical omics study reveals that the immunosuppressant ATG profoundly impacts the DNA methylome of KTx recipients and identifies biomarkers that could be used in pre-Tx screening of patients vulnerable to infection, thereby informing immunosuppression strategies post-Tx.

15

项与抗人胸腺细胞免疫球蛋白相关的新闻（医药）

2025-04-20

·医脉通

2025《CSCO造血干细胞移植治疗血液系统疾病指南》推荐：贝舒地尔引领cGVHD二线治疗新格局，rATG为GVHD预防保驾护航

2025年4月18日，中国临床肿瘤学会（CSCO）在山东济南召开指南发布会，国内血液肿瘤领域权威专家共同见证的重磅更新。本次指南基于最新临床研究证据，对造血干细胞移植后移植物抗宿主病（GVHD）的预防和治疗方案进行了更新。其中，全球首个高选择性ROCK2靶向抑制剂贝舒地尔在慢性移植物抗宿主病（cGVHD）二线治疗中的核心地位获得进一步确认；兔抗人胸腺细胞免疫球蛋白（rATG）作为急性GVHD（aGVHD） /cGVHD预防的基石药物，始终保持着不可替代的经典地位，指南历次更新均维持其I级治疗推荐。本文选取指南更新要点进行解读，重点阐述GVHD的规范化治疗策略，以期为临床实践提供参考。贝舒地尔获2025 CSCO指南Ⅰ级推荐，领航二线新格局一线变化：cGVHD一线治疗中II级推荐删除泼尼松+奥法妥木单抗(2B类）和泼尼松+伊布替尼（ibrutinib） (2B类)1二线变化：贝舒地尔地位跃迁，在cGVHD二线治疗中调整为Ⅰ级推荐1，并领航二线靶向药物，西罗莫司（Sirolimus）由I级推荐（2A类）下降至Ⅱ级推荐（2A类），新增艾里克单抗（Axatilimab）为Ⅱ级推荐（2A类），新增体外光分离置换术(ECP)(2C类) 为Ⅲ级推荐1。表1 《CSCO 造血干细胞移植治疗血液系统疾病指南(2025版) 》对于cGVHD的二线治疗推荐1循证护航：贝舒地尔治疗cGVHD实现高效缓解，改善生存安全性良好：贝舒地尔治疗cGVHD，感染2-3和血细胞减少的发生率低rATG作为预防aGVHD和cGVHD I级用药推荐，地位稳固预防aGVHD：维持原始推荐，较2023年CSCO指南推荐用药及级别无变化1预防cGVHD：II级推荐中间充质干细胞（MSCs）证据等级由2A类调整为1B类，仍保持II级推荐意见1ATG是目前急慢性GVHD预防的重要手段，rATG作为唯一拥有GVHD预防适应症的进口ATG，自2021年被CSCO作为I级用药推荐5，至今地位稳固，为移植患者筑起抗GVHD的生命防线，护航患者生命健康。表2 《CSCO 造血干细胞移植治疗血液系统疾病指南(2025版) 》对于GVHD的预防推荐1总结综上所述，2025版《CSCO 造血干细胞移植治疗血液系统疾病指南》的更新，明确了贝舒地尔作为cGVHD二线治疗的重要地位，其独特的ROCK2靶向机制通过促进免疫稳态恢复和抑制甚至逆转纤维化，可以在治疗GVHD的同时、保留移植物抗白血病（GVL）效应（降低原发病复发风险），在保证卓越疗效的同时展现出显著的安全性优势；而rATG则继续巩固其在急、慢性GVHD预防中的I级推荐地位，这些重要的推荐为临床提供了从预防到治疗的全程优化管理策略。缩写：GVHD：移植物抗宿主病aGVHD：急性移植物抗宿主病cGVHD：慢性移植物抗宿主病CMV：巨细胞病毒ORR：客观缓解率MMF：霉酚酸酯MTX：甲氨蝶呤CsA：环孢素FK506：他克莫司ATG：抗胸腺细胞球蛋白HSCT：造血干细胞移植GVL：移植物抗白血病效应PT/CY：移植后环磷酰胺PR：部分缓解CR：完全缓解MSCs：间充质干细胞参考文献：1. 中国临床肿瘤学会(CSCO). 造血干细胞移植治疗血液系统疾病指南(2025版).2. Wang Y, et al. BMC Med. 2024;22(1):142.3. Corey Cutler, et al. Blood. 2021 Dec 2;138(22）:2278-2289.4. Inamoto Y, et al.Am J Hematol.2024 Oct;99(10):1917-1926.5.中国临床肿瘤学会(CSCO). 造血干细胞移植治疗血液系统疾病指南(2021版).MAT-CN-2507718.V1.0.2025.04免责声明：该信息仅作医学和科研参考，赛诺菲不建议以任何与您所在国家所批准的处方信息不符的方式使用本产品。本材料仅供医疗卫生专业人士使用。END医脉通是专业的在线医生平台，“感知世界医学脉搏，助力中国临床决策”是平台的使命。医脉通旗下拥有「临床指南」「用药参考」「医学文献王」「医知源」「e研通」「e脉播」等系列产品，全面满足医学工作者临床决策、获取新知及提升科研效率等方面的需求。

CSCO会议临床1期临床终止

2024-11-21

·Endpoints

Samsung Bio's new $668M client; Sanofi expands a factory in France

Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Samsung Biologics has secured a number of manufacturing deals worth a total of $668 million with an unnamed European pharma client, the CDMO said Tuesday. The deals expire in 2031. Sanofi is investing €40 million ($42.1 million) to expand its bioproduction facility in Lyon, France, the company said Friday. In particular, €25 million ($26.3 million) will be used to make the antibody for Thymoglobulin and €15 million ($15.7 million) to make monoclonal antibodies for type 1 diabetes clinical-stage therapies. The UK regulatory agency MHRA has appointed University of Oxford professor Anthony Harnden as its new chair, according to a Tuesday release. Harnden replaces Stephen Lightfoot, who stepped down in April 2023. LIfT BioSciences has launched a new subsidiary called Eolaíocht Bhitheach LIfT Teoranta, which will operate from Galway, Ireland, the company said Monday. The subsidiary will collaborate with the University of Galway and medical tech manufacturer HookeBio to provide manufacturing and clinical services. Lonza has manufactured its first batch of drug products at its mammalian manufacturing facility in Portsmouth, NH, the company said Wednesday. Convergent Therapeutics has received its first shipment of the radioisotope actinium-225 from Cardinal Health to make its Phase 1/2 prostate cancer radiopharmaceutical, according to a Monday release. Meiji Seika Pharma is investing in the CDMO and mRNA vaccines company Arcalis to improve its supply of mRNA vaccines in Japan, according to a Thursday release. Arcalis will make the API for Meiji’s Covid-19 vaccine. No financial details were disclosed. India-based Unexo Life Sciences was handed an FDA warning letter published Tuesday. It outlined two key issues: failure to produce certain batch record data and dirty air conditioner vents above drug production areas. The White House published a report , dubbed Building a Vibrant Domestic Biomanufacturing Ecosystem, on Friday. It states that the US needs more infrastructure and technology to produce drugs domestically and outlines 11 actions that policymakers should consider to improve manufacturing.

疫苗信使RNA高管变更

2024-11-19

·Pharma Manufacturing

Sanofi invests $42M in Lyon for drug production

Sanofi has announced a €40 million investment in its Lyon Gerland bioproduction site, enhancing its capabilities in immunology-focused drug production. The investment supports the production of Thymoglobulin, used in transplantation, and localizes the manufacturing of TZIELD, a type 1 diabetes treatment, to France. Of the total investment, €25 million will fund the development of a second-generation polyclonal antibody for transplant patients, increasing production capacity and improving environmental sustainability. An additional €15 million will be allocated to producing monoclonal antibodies for type 1 diabetes treatment, previously manufactured outside the EU. Modernization efforts at the Lyon site began in mid-2024, with the first industrial batches of the updated polyclonal antibody expected in 2025 and commercial availability in 2027. Production of the existing treatment continues alongside these upgrades. Similarly, production of the immunomodulatory type 1 diabetes treatment will begin in late 2025, targeting market availability in 2027.

100 项与抗人胸腺细胞免疫球蛋白相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
器官移植排斥	日本	Sanofi KK	2011-04-22
细菌感染	澳大利亚	Sanofi-Aventis Australia Pty Ltd.	2008-07-18
移植物抗宿主病	日本	Sanofi KK	2008-07-16
再生障碍性贫血	韩国	Sanofi-Aventis Korea Co., Ltd.	1993-01-19
心脏移植排斥反应	韩国	Sanofi-Aventis Korea Co., Ltd.	1993-01-19
肾移植排斥反应	韩国	Sanofi-Aventis Korea Co., Ltd.	1993-01-19

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
心源性猝死	临床3期	英国	Genzyme Corp.	2011-01-01
再灌注损伤	临床3期	英国	Genzyme Corp.	2011-01-01
慢性移植物抗宿主病	临床3期	加拿大	Genzyme Corp.	2010-04-01
白血病	临床3期	加拿大	Genzyme Corp.	2010-04-01
急性髓性白血病	临床3期	美国	Genzyme Corp.	2007-08-01
肺移植排斥反应	临床3期	美国	Genzyme Corp.	2006-01-01
原发性移植物功能障碍	临床3期	美国	Genzyme Corp.	2006-01-01
1型糖尿病	临床2期	美国	Genzyme Corp.	2010-04-01
终末期肾脏病	临床2期	美国	Sanofi	2010-03-01
造血干细胞移植	临床2期	美国	Genzyme Corp.	2009-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASH2024	N/A	难治性重度再生障碍性贫血	-	Rabbit ATLG	繭壓簾夢鹽遞顧顧餘襯(鏇憲壓膚範醖顧蓋觸齋) = 齋襯簾積蓋壓衊蓋網鹽範襯壓廠淵網願願鬱鹽 (淵餘簾網網選鹽齋窪齋 ) 更多	-	2024-12-08
				ATG	繭壓簾夢鹽遞顧顧餘襯(鏇憲壓膚範醖顧蓋觸齋) = 淵齋顧窪衊淵構艱鬱繭範襯壓廠淵網願願鬱鹽 (淵餘簾網網選鹽齋窪齋 ) 更多
3537 (ASH2024)	N/A	Sveinsson脉络膜视网膜萎缩 CMV \| EBV	406	rATG	艱壓衊艱鑰襯鏇鏇構顧(顧蓋醖選餘顧膚選艱繭) = 顧繭簾蓋齋願膚衊餘顧壓壓選憲鏇窪獵衊鹽選 (窪鹽鬱鹹齋鏇鑰網壓餘, 0.71 ~ 0.81) 更多	积极	2024-12-08
				ATLG	艱壓衊艱鑰襯鏇鏇構顧(顧蓋醖選餘顧膚選艱繭) = 鹽蓋獵築遞顧憲選膚餘壓壓選憲鏇窪獵衊鹽選 (窪鹽鬱鹹齋鏇鑰網壓餘, 0.65 ~ 0.83) 更多
NCT02582775 (CTgov)	临床2期	大疱性表皮松解	17	Donor mesenchymal stem cell infusions+Fludarabine+Cyclophosphamide+Thymoglobulin+Tacrolimus+mycophenolate mofetil (RDEB: HCT Plus MSC Arm B)	製簾壓網簾糧蓋窪膚願 = 築糧齋鹽觸襯齋觸顧繭築糧餘獵蓋顧襯糧糧淵 (廠觸廠齋鹽顧壓蓋鹹夢, 鏇鹹簾艱獵簾鑰簾鑰襯 ~ 淵憲窪襯顧顧鑰衊網糧) 更多	-	2024-09-19
				Donor mesenchymal stem cell infusions+Fludarabine+Cyclophosphamide+Thymoglobulin+Tacrolimus+mycophenolate mofetil (RDEB: HCT Plus MSC Arm E)	製簾壓網簾糧蓋窪膚願 = 鹽製衊壓衊餘夢艱積簾築糧餘獵蓋顧襯糧糧淵 (廠觸廠齋鹽顧壓蓋鹹夢, 製壓蓋顧蓋壓壓願淵獵 ~ 範鑰觸醖鏇夢範襯鹹顧) 更多
EHA2024	N/A	血液肿瘤	211	ATG-Genzyme (ATG-G) ≤6 mg/kg	餘網壓選繭蓋壓顧餘積(淵壓鹽積鏇餘衊衊蓋鹹) = 蓋膚艱選構鏇觸選醖構鬱簾膚壓襯齋選淵觸鹹 (網顧範鏇網選構製齋獵, 40.8% ~ 56.3) 更多	-	2024-05-14
				ATG-Fresenius (ATG-F) 20mg/kg	觸憲鑰齋艱窪蓋築糧觸(願築繭艱願壓衊醖蓋憲) = 餘選窪衊積積顧艱遞艱鏇壓鹹壓夢積築築鏇夢 (網願膚壓窪齋繭鏇構齋, 15.7% ~ 26.8) 更多
TBI-ATG-BASED CONDITIONING REGIMEN (EHA2024)	N/A	外周T细胞淋巴瘤	-	TBI-ATG-based conditioning regimen	選網衊遞繭餘夢窪範鬱(齋蓋獵觸顧鬱製鹽簾範) = 夢壓網窪鹹鹹構廠憲網醖艱獵構顧鬱選糧鹽鏇 (鹹鏇製構範鑰觸窪鏇廠, 57.55% ~ 77.79%) 更多	积极	2024-05-14
Pubmed \| Diabetes Care	N/A	2型糖尿病	6	Low-dose Antithymocyte Globulin (ATG) 2.5 mg/kg	壓夢積築鬱鑰餘網鬱膚(糧選製醖鏇鑰鏇鏇淵製) = 獵範窪餘夢鹹範構餘築鑰壓範製構廠糧簾觸淵 (鬱獵衊獵艱製顧餘糧製 ) 更多	积极	2024-02-01
Tandem Meetings ASTCT and CIBMTR2024	N/A	血液肿瘤	-	Rabbit Antithymocyte (High pre-HCT AUC and low post-HCT)	齋醖構艱衊膚鏇艱簾蓋(鏇構獵齋醖廠憲積獵築) = 選鹹廠艱積壓鬱顧壓壓願簾遞餘築醖糧憲鏇鏇 (壓齋鏇襯築窪艱夢夢糧, 76.3 ~ 96.7)	-	2024-02-01
				Rabbit Antithymocyte (Low pre-HCT and post-HCT AUCs)	齋醖構艱衊膚鏇艱簾蓋(鏇構獵齋醖廠憲積獵築) = 壓範願築獵鹽願積襯築願簾遞餘築醖糧憲鏇鏇 (壓齋鏇襯築窪艱夢夢糧, 49.1 ~ 80.1)
Tandem Meetings ASTCT and CIBMTR2024	N/A	镰状细胞血症	28	Thiotepa, Fludarabine, Thymoglobulin, Low Dose Cyclophosphamide, 200 Cgy TBI and Post-Transplant Cyclophosphamide	鑰襯鹹製廠築鏇鏇蓋鬱(網繭膚餘壓觸鹽襯夢構) = 範鏇鹽製鏇願觸窪積鏇選築餘鬱憲選遞顧鹽鬱 (範艱鹹鹹壓製醖憲願鑰 ) 更多	积极	2024-02-01
NCT02441803 (CTgov)	临床2期	急性髓性白血病	11	Stem Cell Infusion+Clofarabine+Fludarabine+Busulfan+Decitabine+Cytarabine+Idarubicin (Matched Sibling Donor Group)	遞願鬱艱積窪壓蓋艱遞 = 簾選餘積願淵簾鏇鑰衊衊鹹範醖繭範窪繭鑰簾 (淵構窪選範齋選醖壓膚, 範餘衊廠鹹觸窪膚餘衊 ~ 廠膚鑰齋醖齋壓膚築網) 更多	-	2024-01-17
				Stem Cell Infusion+Clofarabine+Fludarabine+Busulfan+Cyclophosphamide+Decitabine+Tacrolimus+mycophenolate mofetil+Cytarabine+Idarubicin (Haploidentical Donor Group)	遞願鬱艱積窪壓蓋艱遞 = 壓鏇築網糧鑰蓋鏇鹽夢衊鹹範醖繭範窪繭鑰簾 (淵構窪選範齋選醖壓膚, 網憲築顧蓋窪構窪積築 ~ 蓋構鏇顧淵壓獵鬱艱鑰) 更多
NCT01850108 (CTgov)	N/A	急性胸部综合征 \| 血红蛋白SC疾病 \| 镰状细胞血症	26	Bone marrow transplantation+Mesna+Fludarabine+Cyclophosphamide (CTX)+Thymoglobulin+Sirolimus+Mycophenolate mofetil (MMF)	夢鏇顧簾艱構鏇製窪築 = 鹹獵憲顧製鹽鏇餘築網願顧範艱壓網構鑰網艱 (齋繭鬱願鬱襯鏇顧獵蓋, 築齋醖鹽齋製蓋蓋蓋遞 ~ 簾鹹窪選網壓淵選淵範) 更多	-	2024-01-10